Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Axonics, Inc.
  6. Summary
    AXNX   US05465P1012

AXONICS, INC.

(AXNX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/21/2021 07/22/2021 07/23/2021 07/26/2021 07/27/2021 Date
64.71(c) 65.36(c) 66.25(c) 64.94(c) 64.03(c) Last
389 940 632 501 286 541 391 795 247 441 Volume
+5.77% +1.00% +1.36% -1.98% -1.40% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 179 M - -
Net income 2021 -73,7 M - -
Net cash position 2021 49,8 M - -
P/E ratio 2021 -34,8x
Yield 2021 -
Sales 2022 245 M - -
Net income 2022 -37,7 M - -
Net cash position 2022 61,3 M - -
P/E ratio 2022 -67,8x
Yield 2022 -
Capitalization 2 941 M 2 941 M -
EV / Sales 2021 16,2x
EV / Sales 2022 11,7x
Nbr of Employees 416
Free-Float 87,8%
More Financials
Company
Axonics, Inc., formerly Axonics Modulation Technologies, Inc., is a medical technology company. The Company is focused on the design, development, and commercialization of sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Its rechargeable SNM system (r-SNM System) delivers mild electrical pulses... 
More about the company
Ratings of Axonics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about AXONICS, INC.
07/19AXONICS : reg; Announces Appointment of Dr. Esteban López to its Board of Direct..
PU
07/19AXONICS, INC. : Change in Directors or Principal Officers, Other Events, Financi..
AQ
07/15AXONICS : reg; Announces Appointment of Dr. Esteban López to its Board of Direct..
BU
07/15Axonics, Inc. Names Esteban López to its Board of Directors
CI
07/14AXONICS : BioLife Solutions Announces Changes to Board of Directors
PR
07/12AXONICS : Barclays Initiates Axonics at Overweight With $74 Price Target
MT
07/11Certain Stock Options of Axonics, Inc. are subject to a Lock-Up Agreement En..
CI
07/11Certain Common Stock of Axonics, Inc. are subject to a Lock-Up Agreement End..
CI
07/11Certain Restricted Stock Units of Axonics, Inc. are subject to a Lock-Up Agr..
CI
07/08AXONICS : reg; to Report Second Quarter 2021 Financial Results on August 5, 2021
BU
06/28AXONICS : Needham Adjusts Axonics' PT to $78 From $72, Citing Non-Rechargeable S..
MT
06/25AXONICS, INC. : Submission of Matters to a Vote of Security Holders, Financial S..
AQ
06/25AXONICS, INC.(NASDAQGS : AXNX) added to Russell 2000 Defensive Index
CI
06/25AXONICS, INC.(NASDAQGS : AXNX) added to Russell 2000 Growth-Defensive Index
CI
06/24AXONICS : Files Pre-Market Approval Supplement to US FDA for Non-Rechargeable Sa..
MT
More news
News in other languages on AXONICS, INC.
2020AXONICS MODULATION TECHNOLOGIES : « gibt Ergebnisse einer Erhebung bei Patienten..
2020AXONICS MODULATION TECHNOLOGIES : « publie les résultats cliniques sur 2áans de ..
2020AXONICS MODULATION TECHNOLOGIES : « berichtet 2-Jahres-Ergebnisse aus der ARTISA..
2020AXONICS MODULATION TECHNOLOGIES : NICE recommande le système Axonics«ár-SNM pour..
2020AXONICS MODULATION TECHNOLOGIES : NICE empfiehlt Axonics« r-SNM System zur Behan..
More news
Analyst Recommendations on AXONICS, INC.
More recommendations
Chart AXONICS, INC.
Duration : Period :
Axonics, Inc. Technical Analysis Chart | AXNX | US05465P1012 | MarketScreener
Technical analysis trends AXONICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 64,03 $
Average target price 72,20 $
Spread / Average Target 12,8%
EPS Revisions
Managers and Directors
Raymond Wayne Cohen Chief Executive Officer & Director
Danny L. Dearen President & Chief Financial Officer
Michael H. Carrel Chairman
Guang Qiang Jiang Chief Technology Officer
Karen Noblett Chief Medical Officer
Sector and Competitors